The powerful master regulatory transcription factor called Bcl6 is key to the survival of a majority of aggressive lymphomas, which arise from the B-cells of the immune system. The protein has long been considered too complex ...
Mar 3, 2013
0
0
(Medical Xpress)—Researchers at UCLA's Jonsson Comprehensive Cancer Center have discovered the mechanism by which an experimental drug known as GCS-100 removes from lymphoma cells a protein that prevents the cells from ...
Oct 15, 2012
0
0
A study led by the group of Didier Trono at EPFL has revealed a crucial survival tactic employed by cancer cells. The scientists have identified a group of proteins, known as "KRAB zinc finger proteins" (KZFPs), that help ...
Feb 12, 2024
0
0
A team of researchers from the Cancer Science Institute of Singapore (CSI Singapore) at the National University of Singapore (NUS), led by Assistant Professor Anand Jeyasekharan, has discovered a unique combination of oncogenes ...
Jul 19, 2023
0
0
DNA mutations are essential to the rapid development of an array of antibody-producing immune cells called B cells that collectively can recognize a vast number of specific targets. But this process can go awry in people ...
May 25, 2022
0
6
Newer therapies are outpacing the current treatment for diffuse large B cell lymphoma, according to data that scientists will deliver from two major clinical trials at the American Society of Hematology (ASH) annual meeting ...
Dec 10, 2021
0
1
The National Institute for Health and Care Excellence (NICE) has recommended a new combination therapy for adults with an aggressive type of non-Hodgkin lymphoma on the NHS in England.
Aug 21, 2020
0
1
A team of researchers investigating how a certain type of drugs can kill cells has discovered that these drugs can do more harm than good when used in combination with other cancer treatments.
Jul 24, 2020
0
2
The National Institute for Health and Care Excellence (NICE) has not recommended a new combination therapy for adults with an aggressive type of non-Hodgkin lymphoma on the NHS in England.
Mar 12, 2020
0
1
A toxin linked to a targeted monoclonal antibody has shown "compelling" antitumor activity in patients with non-Hodgkin lymphomas who were no longer responding to treatment, according to a report from Dana-Farber Cancer Institute.
Dec 10, 2013
0
0
Diffuse large B-cell lymphoma (DLBL, DLBCL, or DLCL) is a type of aggressive non-Hodgkin lymphoma. It accounts for approximately 40% of lymphomas among adults. The median age at diagnosis is 70 years, but it also occurs in children and young adults. As with most non-Hodgkin lymphomas, there is a male predominance, although primary cutaneous diffuse large B cell lymphoma is more common in women. Of all cancers involving the same class of blood cell, 31% of cases are DLBL.
This text uses material from Wikipedia licensed under CC BY-SA
